Abstract |
A successful therapy is presented using the antiplatelet agent abciximab, alone, in an ST-segment elevation acute myocardial infarction. The patient was treated in a center with permanent catheterization facilities. Clinical trials are necessary to validate the efficacy and the cost-effectiveness of this clinical decision and therapeutic option.
|
Authors | A Mesquita, J Baptista, J Palos, R Seabra-Gomes |
Journal | The Journal of invasive cardiology
(J Invasive Cardiol)
Vol. 11
Issue 6
Pg. 379-82
(Jun 1999)
ISSN: 1042-3931 [Print] United States |
PMID | 10745556
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Abciximab
|
Topics |
- Abciximab
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Coronary Angiography
- Electrocardiography
- Female
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use)
- Myocardial Infarction
(diagnosis, drug therapy, physiopathology)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Treatment Outcome
|